BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
12.15
-0.10 (-0.82%)
Nov 7, 2025, 4:00 PM EST - Market closed
BBOT Employees
BridgeBio Oncology Therapeutics had 62 employees as of December 31, 2024.
Employees
62
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,411,290
Market Cap
962.24M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BBOT News
- 4 days ago - BBOT to Participate in the Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 8 days ago - BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS) - GlobeNewsWire
- 14 days ago - Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia - GlobeNewsWire
- 15 days ago - BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 25 days ago - BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 2 months ago - BBOT to Participate in Upcoming September Investor Healthcare Conferences - GlobeNewsWire
- 3 months ago - BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition - GlobeNewsWire